Vinblastine infusion in non-Hodgkin's lymphomas: lack of total cross-resistance with vincristine.
Historically, vinblastine given by intravenous bolus injection has not been an effective treatment for non-Hodgkin's lymphomas; vincristine has displayed greater activity. Also, vinblastine has generally been considered to be cross-resistant with vincristine in such patients. In an attempt to overcome these obstacles, a protracted infusion of vinblastine was administered (0.5-1.5 mg/m2 per day for 5 days) and repeated every 3 weeks. Partial responses were observed in 4 of 29 (14%) patients with a variety of non-Hodgkin's lymphoma lasting 2.4, 2.4, 5.5, and 9.0 months. Just prior to treatment the responding patients had received and eventually become refractory to vincristine. These data show a lack of total cross-resistance between vinblastine and vincristine which might have important therapeutic implications in this disease.
Piedmont Oncology Association, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
D V
DV
Jackson
C L
CL
Spurr
M E
ME
Caponera
D R
DR
White
H B
HB
Muss
M D
MD
Pavy
G P
GP
Sartiano
P J
PJ
Zekan
E A
EA
Hire
D000328:Adult; D000368:Aged; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000494:pharmacology*
D014750:Vincristine; D014747:Vinblastine